GEHC

GE HealthCare Technologies
D

GEHC

Arincen60/100B

GE HealthCare Technologies financials

Yes. GE HealthCare Technologies earned 1.76B USD of net income over the last twelve months, 8.5% of its revenue. It made a profit in 7 of its 7 fiscal years since 2019.

Revenue (TTM)
20.61B USD
Net income (TTM)
1.76B USD
Free cash flow (TTM)
1.21B USD
Cash and short-term investments
2.85B USD
Total debt
10.41B USD
Shareholders' equity
11.61B USD

Cash, debt and equity as of 30 Sept 2026.

GE HealthCare Technologies earnings

Next earnings · Q4 FY2026
EPS estimate
1.55 USD
Revenue estimate
5.92B USD
Last quarter · Q3 FY2026
EPS1.34Beat +11.7%Revenue5.51BBeat +3.0%

Revenue

ReportedEstimate

EPS

ReportedEstimate
PeriodReport dateEPS estimateReported EPSSurpriseEPS growthRevenue estimateReported revenueSurpriseRevenue growth
Q3 FY20271.42——+6.22%5.75B——+4.25%
Q2 FY20271.26——+11.60%5.54B——+4.65%
Q1 FY20271.11——+12.43%5.36B——+4.52%
Q4 FY20261.55——+7.64%5.92B——+3.97%
Q3 FY20261.201.34+11.67%+25.23%5.35B5.51B+3.02%+7.19%
Q2 FY20261.041.13+8.65%+6.60%5.26B5.30B+0.59%+5.77%
Q1 FY20261.040.99-4.81%-1.98%5.04B5.13B+1.76%+7.41%
Q4 FY20251.401.44+2.86%-0.69%5.61B5.70B+1.51%+7.13%
Q3 FY20251.051.07+1.90%-6.14%5.09B5.14B+1.10%+5.76%
Q2 FY20250.921.06+15.47%+6.00%4.97B5.01B+0.66%+3.45%

GE HealthCare Technologies growth and profitability

Full income statement
Revenue (TTM)
20.61B USD
Net income (TTM)
1.76B USD
Gross margin
43.27%
Operating margin
13.21%
Net margin
8.54%

Revenue / Net income

Revenue Net income Net margin
PeriodRevenueGrowthNet incomeGrowthGross marginOperating marginNet marginEBITDAGrowth
FY202520.63B+4.84%2.08B+4.57%39.99%13.39%10.10%3.79B+3.25%
FY202419.67B+0.61%1.99B+27.10%41.71%13.34%10.13%3.67B+4.36%
FY202319.55B+6.60%1.57B-18.16%40.52%12.45%8.02%3.51B+11.00%
FY202218.34B+4.30%1.92B-14.73%39.14%13.75%10.45%3.17B-10.59%
FY202117.59B+2.45%2.25B-83.77%40.80%15.89%12.78%3.54B+3.93%

How GE HealthCare Technologies makes its money

Revenue20.63B 100.0%
Cost of revenue12.38B 60.0%
Gross profit8.25B 40.0%
Research and development1.26B 6.1%
Selling and administration4.23B 20.5%
Operating income2.76B 13.4%
Tax614.00M 3.0%
Other expense64.00M 0.3%
Net income2.08B 10.1%

FY2025, in USD. Each band is as wide as its money; the percentage is its share of revenue.

GE HealthCare Technologies revenue breakdown

By product

FY2025
Imaging: 60.7%PCS: 20.3%PDx: 19.0%60.7%Imaging20.3%PCS19.0%PDx
SegmentRevenueShare of revenueChange on the year
Imaging9.25B60.7%+4.4%
PCS3.09B20.3%-1.2%
PDx2.90B19.0%+15.6%

By region

FY2025
Other Countries: 45.7%United States: 44.4%China: 9.8%45.7%Other Countries44.4%United States9.8%China
RegionRevenueShare of revenueChange on the year
Other Countries9.43B45.7%+5.7%
United States9.17B44.4%+6.4%
China2.03B9.8%-4.9%

Operating and free cash flow

Full cash flow statement
Operating cash flow Free cash flow
Fiscal yearOperating cash flowFree cash flow
FY20251.99B1.51B
FY20241.95B1.55B
FY20232.10B1.71B
FY20222.11B1.80B
FY20211.61B1.36B
FY20201.69B1.43B
FY20191.99B1.66B

GE HealthCare Technologies financial health

Full balance sheet
Cash and short-term investments
2.85B USD
Total debt
10.41B USD
Net cash
-7.55B USD
Free cash flow (TTM)
1.21B USD
Current ratio
1.30
Debt to equity
0.90
Piotroski score
6 / 9
Altman Z-score
1.94

Cash, debt and free cash flow

Cash and short-term investments Total debt Free cash flow
Fiscal yearCash and short-term investmentsTotal debtFree cash flow
FY20254.51B10.00B1.51B
FY20242.89B9.38B1.55B
FY20232.50B9.86B1.71B
FY20221.45B8.64B1.80B
FY2021556.00M437.00M1.36B

Assets, liabilities and equity

Total assets Total liabilities Shareholders' equity
Fiscal yearTotal assetsTotal liabilitiesShareholders' equity
FY202536.91B26.31B10.38B
FY202433.09B24.44B8.45B
FY202332.45B25.14B7.13B
FY202227.54B17.95B9.36B
FY202126.31B9.41B16.66B
FY202024.23B9.25B14.73B
FY2019———

GE HealthCare Technologies valuation

Price to earnings ratio (TTM)
21.34
Forward P/E (FY2026)
16.42
Price to sales (TTM)
1.81
Price to book
3.21
EV / EBITDA (TTM)
13.97

Capital structure

Market capitalization
37.25B USD
+
Total debt
10.41B USD
−
Cash and short-term investments
2.85B USD
=
Enterprise value
44.80B USD

Valuation over time

P/EForward P/EForward P/E · EstimateEstimate
Fiscal yearP/EForward P/EP/SP/BEV/EBITDA
FY2028 (est.)13.45————
FY2027 (est.)14.9313.45———
FY2026 (est.)16.4214.93———
Now (TTM)21.3415.121.813.2113.97
FY202517.9916.351.823.6111.34
FY202417.8917.191.814.2211.49
FY202325.4318.011.804.9312.11
FY202213.8315.281.442.8310.64
FY202112.24—1.551.647.67

GE HealthCare Technologies against its own history

Each figure in the latest fiscal year against the same figure from FY2021 to FY2025: the range, its median (the line) and the latest (the dot, green on the good side of the median). The P/E is today's against its daily readings of five years.

Its peers: DexCom, Edwards Lifesciences, Boston Scientific, Zimmer Biomet Holdings, Glaukos, and Penumbra, the US Medical - Devices companies closest to it in size, each in its own latest fiscal year: their median (the line) and its rank among them, first being the best.

  • P/E (today)Above its median21.3
    13.130.8
  • Gross marginBelow its median40.0%
    39.1%41.7%
    Against its peers: 7 of 7Peers' median 68.1%
  • Operating marginAt its median13.4%
    12.5%15.9%
    Against its peers: 6 of 7Peers' median 18.1%
  • Net marginBelow its median10.1%
    8.0%12.8%
    Against its peers: 5 of 7Peers' median 13.5%
  • Return on equityBelow its median20.1%
    13.5%23.6%
    Against its peers: 2 of 7Peers' median 11.1%
  • Free cash flow marginLowest in 5 years7.3%
    7.3%9.8%
    Against its peers: 6 of 7Peers' median 18.1%
  • Revenue growthAbove its median4.8%
    0.6%6.6%
    Against its peers: 7 of 7Peers' median 16.5%
  • EPS growthAt its median4.8%
    -28.4%43.7%
    Against its peers: 4 of 6Peers' median 47.2%
  • Debt to EBITDAAt its median2.64×
    0.12×2.81×
    Against its peers: 5 of 6Peers' median 1.02×
  • Current ratioHighest in 5 years1.18
    0.971.18
    Against its peers: 7 of 7Peers' median 2.85

Peers: US companies of the same industry (of its sector when the industry has too few) from a tenth to ten times its market value, the six closest in size. Updated weekly.

GE HealthCare Technologies dividends

Annual dividend
0.16 USD
Dividend yield (indicated)
0.19%
Payout ratio
3.76%
Years of dividend growth
2
Frequency
Quarterly
Next payment
0.04 USD
Last ex-dividend date
23 Oct 2026
Next payment date
13 Nov 2026

Dividends per share

Year202520242023
Dividends per share0.140.120.09

GE HealthCare Technologies ownership

Institutions
87.73%
Institutional holders
1,271 (-48)
Free float
99.67%

Who owns the shares

Institutions 87.7% Others 12.3%
As of 30 Jun 2026

Shares free to trade

Free float 450.65M shares ·99.7% Closely held 1.49M shares ·0.3%

Closely held shares belong to insiders, founders and owners of more than 5%, and seldom change hands. The free float is the rest: the shares anyone can buy and sell.

Insider trading

QuarterPurchasesSalesShares acquiredShares disposed of
Q3 202600106.97K33.62K
Q2 202680154.34K5.54K
Q1 202600613.76K74.61K
Q3 20250015.56K35.60K

Shares outstanding

Basic shares Diluted shares Change in diluted shares
Fiscal yearBasic sharesDiluted sharesChange in diluted shares
FY2025456.52M460.27M+0.28%
FY2024456.00M459.00M+0.22%
FY2023455.00M458.00M+0.90%
FY2022453.93M453.93M-0.17%
FY2021454.71M454.71M0.00%

Common questions about GE HealthCare Technologies's financials

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.